Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | PRKCB | P05771 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCH | P24723 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26188030 | 0.82 | PRKD3 (0.43) | PYGBPRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL17866069 | 0.81 | PYGB (0.42) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL6015980 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL15201698 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL9521214 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL9563973 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL15963880 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL9521223 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL8668910 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 | |
| SCHEMBL7163178 | 0.80 | PTGS1 (0.40) | PYGBPTGS1PTGS2SLC2A1AMDHD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667661-B2 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | BIOMETRIX TECHNOLOGY INC (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667661-B2 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | BIOMETRIX TECHNOLOGY INC (KR) | 2023-06-06 | — | — | US | disclosed |
| US-20210300959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC (KR) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME | H1-3, H1-4, H1-5 | PYGB 4366/4885ADORA1 1090/4885PTGS1 3675/4885 |
| US-11667661-B2 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same | H1-3, H1-4, H1-5 | PYGB 4090/4885ADORA1 871/4885PTGS1 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.